Skip to main content
Premium Trial:

Request an Annual Quote

We Suggest the Head-in-the-Sand Approach

GTO recommends the first few paragraphs of this story from the San Francisco Chronicle, which covers Ernst & Young's recent report on the biotech industry. "Financing from all sources topped $21.3 billion for U.S. biotech companies in 2007, and the $5.5 billion contributed by venture capital firms beat the record set in the heady year of 2000," according to the article.

But if you must venture past the beginning of the story, brace yourself for less rosy stats: E&Y's life sciences director says there could be tough times ahead, and that the biotech sector has raised 60 percent less so far this year than it did last year.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.